ArticleCancer control : journal of the Moffitt Cancer Center
Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionThe Cancer Inflammation Prognostic Index (CIPI) is a composite biomarker that integrates carcinoembryonic antigen (CEA), neutrophil, and lymphocyte counts to reflect both tumor burden and systemic inflammation. Although CIPI has demonstrated prognostic value in early-stage and previously treated metastatic colorectal cancer, its role in untreated, de novo metastatic colon cancer remains unclear.MethodsThis multicenter, retrospective cohort study included 287 patients diagnosed with de novo metastatic colon cancer between 2010 and 2023. CIPI was calculated by multiplying serum CEA by the neutrophil-to-lymphocyte ratio, and the optimal cutoff value for overall survival (OS) was determined using receiver operating characteristic (ROC) curve analysis. Patients were stratified into low- and high-CIPI groups based on this threshold.ResultsThe median follow-up period was 4.0 years, during which 202 patients (70.4%) died. The optimal CIPI cutoff value for OS was 86.09. Median OS was significantly shorter in the high-CIPI group compared with the low-CIPI group (36.0 vs 14.5 months, p < 0.001). In multivariable Cox regression analysis, a high CIPI remained an independent prognostic factor for OS (hazard ratio, 2.29; 95% confidence interval, 1.65-3.17; p < 0.001). In a separate multivariable model, elevated CEA was also independently associated with poorer overall survival.ConclusionCIPI independently predicts overall survival in patients with de novo metastatic colon cancer. Its simplicity, cost-effectiveness, and derivation from routine laboratory data make it a practical and promising tool for baseline risk stratification and individualized follow-up planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.